Literature DB >> 27746981

IL-1 receptor antagonist in sepsis: new findings with old data?

David Grimaldi1, Eduardo Wilfrido Goicoechea Turcott1, Fabio Silvio Taccone1.   

Abstract

Entities:  

Year:  2016        PMID： 27746981      PMCID： PMC5059273          DOI： 10.21037/jtd.2016.08.51

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  The Future of Critical Care Medicine: Integration and Personalization.

Authors:  Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2016-02       Impact factor: 7.598

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

Review 3.  Sepsis: a roadmap for future research.

Authors:  Jonathan Cohen; Jean-Louis Vincent; Neill K J Adhikari; Flavia R Machado; Derek C Angus; Thierry Calandra; Katia Jaton; Stefano Giulieri; Julie Delaloye; Steven Opal; Kevin Tracey; Tom van der Poll; Eric Pelfrene
Journal:  Lancet Infect Dis       Date:  2015-04-19       Impact factor: 25.071

Review 4.  Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults.

Authors:  Robert A Raschke; Roxanne Garcia-Orr
Journal:  Chest       Date:  2011-07-07       Impact factor: 9.410

5.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

6.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

Review 7.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Nat Rev Immunol       Date:  2013-11-15       Impact factor: 53.106

8.  Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Authors:  C J Fisher; G J Slotman; S M Opal; J P Pribble; R C Bone; G Emmanuel; D Ng; D C Bloedow; M A Catalano
Journal:  Crit Care Med       Date:  1994-01       Impact factor: 7.598

9.  Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Authors:  Bita Shakoory; Joseph A Carcillo; W Winn Chatham; Richard L Amdur; Huaqing Zhao; Charles A Dinarello; Randall Q Cron; Steven M Opal
Journal:  Crit Care Med       Date:  2016-02       Impact factor: 7.598

Review 10.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130
View more
  4 in total

1.  Piperlongumin Improves Survival in the Mouse Model of Sepsis: Effect on Coagulation Factors and Lung Inflammation.

Authors:  Zhendong Fang; Xianwei Zhang; Yueyue Huang; Hongmin Zhou; Yilun Lu; Yuanyuan Sun; Fanrong Ye; Songzan Qian; Lingling Pan; Wenjing Chen; Hao Jiang; Jingye Pan
Journal:  Inflammation       Date:  2022-07-13       Impact factor: 4.657

2.  Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.

Authors:  Juan Salvatierra; Úrsula Torres-Parejo; Francisco Anguita-Santos; Ismael Francisco Aomar-Millán; Naya Faro-Miguez; José Luis Callejas-Rubio; Ángel Ceballos-Torres; María Teresa Cruces-Moreno; Francisco Javier Gómez-Jiménez; José Hernández-Quero
Journal:  Intern Emerg Med       Date:  2021-01-05       Impact factor: 3.397

3.  VISTA: A Target to Manage the Innate Cytokine Storm.

Authors:  Mohamed A ElTanbouly; Yanding Zhao; Evelien Schaafsma; Christopher M Burns; Rodwell Mabaera; Chao Cheng; Randolph J Noelle
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

Review 4.  New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.

Authors:  Mahrukh S Rizvi; Alice Gallo De Moraes
Journal:  Crit Care Explor       Date:  2021-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.